A recent systematic review published in the Cochrane Database of Systematic Reviews has found insufficient evidence to support the use of medical cannabis for improving sleep in individuals with insomnia. Conducted by researchers from the Cochrane Associate Centre at Universidad Hospital Italiano de Buenos Aires and the University of Manitoba, the review highlights a discrepancy between the popularity of cannabis as a sleep aid and the available scientific evidence.
Read More
Insomnia is a prevalent sleep disorder that affects people worldwide, leading to challenges such as difficulty falling asleep, frequent awakenings, and feeling unrefreshed upon waking. Chronic insomnia can increase the risk of anxiety and depression, making effective treatments a public health priority. Existing therapies range from cognitive behavioral therapy to pharmacological options, but their effectiveness can vary.
Medical cannabis, which differs from recreational products in its standardized formulations, consists of specific ratios of cannabinoids like tetrahydrocannabinol (THC) and cannabidiol (CBD). Despite anecdotal claims of its effectiveness as a sleep aid, there is ongoing debate among sleep researchers about its actual benefits.
The Cochrane review analyzed nine studies involving 537 adults aged 18 to 76, focusing primarily on individuals with primary insomnia. Most trials compared medical cannabis to placebos, with one trial comparing it to amitriptyline, an antidepressant often used for sleep issues.
The review's primary outcome revealed that medical cannabis did not demonstrate significant improvements in sleep quality, total sleep time, or daytime functioning compared to placebo. Additionally, participants who used medical cannabis reported more mild adverse effects, such as dry mouth and dizziness.
While there was a slight indication that medical cannabis may improve quality of life, the authors caution that the certainty of this finding is low. The overall quality of the studies was rated as low to very low due to high bias risks, inconsistent results, small sample sizes, and limited representation of diverse populations. Most participants were younger women, which raises concerns about the applicability of the findings to older adults or those with comorbid health issues.
The authors conclude that current evidence does not convincingly support the use of medical cannabis for insomnia, emphasizing that more rigorous research is needed. Dr. Lucia Varela, the lead author, noted that the uncertainty of the existing studies means no reliable conclusions can be drawn at this time. Dr. Luis Garegnani echoed this sentiment, urging both patients and clinicians to acknowledge this uncertainty and consider individual circumstances until more robust evidence is available.
The review underscores the necessity for further investigations into the effects of medical cannabis on insomnia before any recommendations can be made.